Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Energy Select Sector SPDR Fund — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Energy Select Sector SPDR Fund trades at $67.9 (market cap $42.98B). The key difference: Energy Select Sector SPDR Fund is far larger — about 5.7× Spyre Therapeutics Inc. Common Stock's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Energy Select Sector SPDR Fund for 68 Days on average.
| SYRE | XLE | |
|---|---|---|
Market Cap | $7.52B | $42.98B |
Volume | 1,441,031 | 27,490,546 |
Sector | Health | — |
52-Week High | $108.92 | $67.61 |
52-Week Low | $22.18 | $42.64 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XLE trades at $67.17, up 1.74% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF's performance is closely tied to oil price dynamics, with recent news highlighting supply disruptions and geopolitical tensions supporting energy sector strength. Key support lies near $65, while resistance is seen around $67.
Outlook remains positive near-term due to oil market tightness, but risks include potential price reversals and sector volatility. Investors should weigh the ETF's concentrated oil and gas exposure against broader energy infrastructure alternatives for diversified income and stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
